Advertisement
Advertisement
IMVT
Immunovant, Inc. Common Stock
33.30
USDSponsored
-0.70
-2.06%
Sep 25, 15:59 UTC -4
Closed
After-Market
33.10
-0.20
-0.60%
IMVT Earnings Reports
Positive Surprise Ratio
IMVT beat 11 of 26 last estimates.
42%
Next Report
Date of Next Report
Nov 09, 2026
Estimate for Q2 27 (Revenue/ EPS)
--
/-$0.74
Implied change from Q1 27 (Revenue/ EPS)
--
/-1.33%
Implied change from Q2 26 (Revenue/ EPS)
--
/+1.37%
Immunovant, Inc. Common Stock earnings per share and revenue
On Aug 06, 2026, IMVT reported earnings of -0.75 USD per share (EPS) for Q1 27, missing the estimate of -0.62 USD, resulting in a -19.48% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +1.17% price change (close before vs. close after earnings).
Looking ahead to Q2 27, 10 analysts forecast an EPS of -0.74 USD, with revenue projected to reach -- USD, implying an decrease of -1.33% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$5.11
Surprise
>+10,000.00%
BlossomHill Therapeutics, Inc. Common Stock
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$1.03
Actual
-$8.75
Surprise
-746.56%
Vogenx Inc Common Stock
Report Date
Sep 17, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.07
Surprise
+1.96%
Benitec Biopharma Inc. Common Stock
Report Date
Sep 14, 2026 For Q4 26
Estimate
-$0.27
Actual
-$0.26
Surprise
+5.59%
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
-$0.05
Surprise
+84.92%
Neuphoria Therapeutics Inc. Common Stock
Report Date
Sep 18, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.95
Surprise
-66.32%
NewcelX Ltd. Ordinary Shares
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$0.54
Actual
-$0.96
Surprise
-77.58%
FAQ
What were Immunovant, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2027?
For Q1 2027, Immunovant, Inc. Common Stock reported EPS of -$0.75, missing estimates by -19.48%, and revenue of $0.00, 0% as expectations.
How did the market react to Immunovant, Inc. Common Stock's Q1 2027 earnings?
The stock price moved up 1.17%, changed from $39.28 before the earnings release to $39.74 the day after.
When is Immunovant, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 09, 2026.
What are the forecasts for Immunovant, Inc. Common Stock's next earnings report?
Based on 10
analysts, Immunovant, Inc. Common Stock is expected to report EPS of -$0.74 and revenue of -- for Q2 2027.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.